| 7.65 0.34 (4.65%) | 05-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.09  |
1-year : | 10.62 |
| Resists | First : | 7.78 |
Second : | 9.09 |
| Pivot price | 6.98 |
|||
| Supports | First : | 6.55 |
Second : | 5.78 |
| MAs | MA(5) : | 7.16 |
MA(20) : | 6.99 |
| MA(100) : | 5.93 |
MA(250) : | 5.25 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 77.3 |
D(3) : | 57.1 |
| RSI | RSI(14): 69.8 |
|||
| 52-week | High : | 7.78 | Low : | 2.85 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VRCA ] has closed It is unclear right now based on current values. 40.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.8 - 7.83 | 7.83 - 7.87 |
| Low: | 7.14 - 7.17 | 7.17 - 7.2 |
| Close: | 7.6 - 7.65 | 7.65 - 7.71 |
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Mon, 06 May 2024
Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last? - Yahoo Finance
Fri, 03 May 2024
Verrica Pharmaceuticals Inc. (VRCA) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Singapore News
Tue, 02 Apr 2024
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewswire
Wed, 27 Mar 2024
Verrica Pharmaceuticals Inc.'s (NASDAQ:VRCA) Shift From Loss To Profit - Simply Wall St
Tue, 26 Mar 2024
Is Verrica Pharmaceuticals Inc (VRCA) Stock About to Get Hot Tuesday? - InvestorsObserver
Sat, 02 Mar 2024
When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -17 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 4.242e+007 (%) |
| Held by Institutions | 1.505e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.49 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 36.1 % |
| Return on Equity (ttm) | -62.6 % |
| Qtrly Rev. Growth | 5.12e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.07 |
| EBITDA (p.s.) | -1.15 |
| Qtrly Earnings Growth | -6.267e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -5.17 |
| Price to Sales | 100.54 |
| Price to Cash Flow | 0 |
| Dividend | 3.84e+006 |
| Forward Dividend | 4.4e+006 |
| Dividend Yield | 50196100% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|